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PURPOSE. The purpose of this study was to describe autofluorescence lifetime characteristics
in Stargardt disease (STGD) using fluorescence lifetime imaging ophthalmoscopy (FLIO) and
to investigate potential prognostic markers for disease activity and progression.
METHODS. Fluorescence lifetime data of 16 patients with STGD (mean age, 40 years; range, 22–
56 years) and 15 age-matched controls were acquired using a fluorescence lifetime imaging
ophthalmoscope based on a Heidelberg Engineering Spectralis system. Autofluorescence was
excited with a 473-nm laser, and decay times were measured in a short (498–560 nm) and
long (560–720 nm) spectral channel. Clinical features, autofluorescence lifetimes and
intensity, and corresponding optical coherence tomography images were analyzed. One-year
follow-up examination was performed in eight STGD patients. Acquired data were correlated
with in vitro measured decay times of all-trans retinal and N-retinylidene-N-retinylethanol-
amine.
RESULTS. Patients with STGD displayed characteristic autofluorescence lifetimes within yellow
flecks (446 ps) compared with 297 ps in unaffected areas. In 15% of the STGD eyes, some
flecks showed very short fluorescence lifetimes (242 ps). Atrophic areas were characterized
by long lifetimes (474 ps), with some remaining areas of normal to short lifetimes (322 ps)
toward the macular center.
CONCLUSIONS. Patients with recent disease onset showed flecks with very short autofluores-
cence lifetimes, which is possible evidence of accumulation of retinoids deriving from the
visual cycle. During the study period, many of these flecks changed to longer lifetimes,
possibly due to accumulation of lipofuscin. Therefore, FLIO might serve as a useful tool for
monitoring of disease progression. (ClinicalTrials.gov number, NCT01981148.)
Keywords: fluorescence lifetimes, fundus autofluorescence, ophthalmic imaging, Stargardt
disease, STGD, fundus flavimaculatus, retinal dystrophies, FLIO
Stargardt disease (STGD) is an autosomal recessive diseasewith a prevalence of approximately 1:10,000.1,2 It is the
most common form of hereditary, recessive macular dystrophy
and is characterized by reduced visual acuity and central
vision loss with onset in childhood or early adulthood.3,4 The
clinical appearance is characterized by yellow flecks at the
level of the RPE distributed around the macula and the
midperiphery of the posterior pole.2 Additionally, in later
stages of disease, there is progressive bilateral atrophy of the
RPE resembling geographic atrophy in age-related macular
degeneration. In the majority of patients (80%), the disease is
caused by a mutation in the ATP-binding cassette transporter
(ABCA4) gene, located within chromosome 1p13.5–8 ABCA4
encodes for the ABCA4 receptor (ABCR), which is a
photoreceptor-specific adenosine triphosphate–binding cas-
sette transporter. ABCR acts as a phospholipid flippase within
the rims and incisures of cone and rod outer segments,
enabling vitamin A derivatives to be transported through the
outer segment disc membranes.9 Dysfunctional ABCR leads to
abnormal lipofuscin accumulation within the RPE.10–12
Lipofuscin is a byproduct of the visual cycle degradation and
consists of various fluorophores including N-retinylidene-N-
retinylethanolamine (A2E).13 Fundus autofluorescence (FAF)
has been established as a tool to visualize lipofuscin
components in vivo10,14 and has significantly promoted our
understanding of the pathophysiology of retinal dystro-
phies.15,16 However, it is still disputed which specific
components of the visual cycle lead to an increase in FAF. A
recent study using mass spectrometry has shown that A2E is
predominantly distributed toward the periphery of the retina
and does not correlate with lipofuscin distribution and
thereby may not contribute to the increase in FAF levels
within the macular center in physiologic aging conditions.17
Furthermore, increased FAF observed in the border zone of
geographic atrophy in age-related macular degeneration has
been attributed to formation of stacked RPE cells and not
primarily to lipofuscin accumulation within individual
cells.18,19 The FAF in STGD is characterized by a general
increase of autofluorescence intensity, particularly in the short
wavelengths, at early stages of the disease.11 With advanced
disease, well-demarcated hyperautofluorescent lesions corre-
sponding to the visible yellowish flecks appear.20–22 Further-
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more, in the later stages of STGD, there is marked hypoauto-
fluorescence in the area of atrophic changes, usually located
at the posterior pole.23,24
Fundus autofluorescence can not only be quantified by
measuring the fluorescence intensity but also by measuring the
time a molecule spends in the excited state before returning to
the ground state. Autofluorescence decay times of endogenous
fluorophores can be measured after excitation with a laser.25
The technique of fluorescence lifetime imaging ophthalmos-
copy (FLIO) has been shown to be reproducible, noninvasive,
and easily deployable in a clinical setting.26,27
Several therapies for STGD, such as gene replacement
therapy and stem cell transplantation, are currently being
assessed in human trials. Evaluating potential therapies may be
difficult because reliable readouts for short-term effects are
currently lacking. Parameters, such as visual acuity or micro-
perimetry, have been used to monitor therapeutic effects, but
may be fraught with bias due to their subjective nature.
Therefore, an objective readout to assess short-term progres-
sion of STGD may be helpful to assess novel treatment
approaches.
The purpose of this study was to perform an extensive
clinical characterization of STGD patients using a fluorescence
lifetime ophthalmoscope and correlate these findings with
optical coherence tomography (OCT) and functional parame-
ters.
METHODS
Patients and Healthy Controls
A total of 32 eyes of 16 patients with a clinical diagnosis of
STGD were included in this study (56% female). A cohort of 15
age-matched healthy subjects with no ophthalmic diseases was
used as a control group (60% female). The mean age was 40.3
6 10.1 years (SD) for the Stargardt group and 40.7 6 9.2 years
(SD) for the controls (P ¼ 0.94). All participants were
Caucasian and phakic and did not have any concomitant
ophthalmic disease (patient characteristics are shown in Tables
1, 2).
According to their phenotypic appearance on color and FAF
images, all Stargardt patients were assigned to one of three
groups from the Fishman classification.28 In Fishman I, retinal
abnormalities as flecks and atrophic areas are restricted to the
macular center; in Fishman II, flecks are spread throughout the
posterior pole, extending anterior to the vascular arcades and/
or nasal to the optic disc; and Fishman III has ‘‘resorbed’’ flecks
and widespread atrophy of the RPE.
Fifty percent of the patients were examined twice after a 12-
month follow-up interval to assess disease activity and
progression.
All participants underwent a general ophthalmologic
examination, and best corrected visual acuity (BCVA; Early
Treatment Diabetic Retinopathy Study [ETDRS] letters) was
measured. Tropicamid 0.5% and phenylephrine HCl 2.5% was
TABLE 1. Demographical and Clinical Data
Characteristics
Stargardt Control
P ValueMean SEM Mean SEM
Number 16 — 15 —
Sex, F, M 9, 7 9, 6
Age, y 40.25 2.53 40.73 2.37 0.94
Age range, y 22–56 — 25–58 —
Age of onset, y 29.00 2.23 — —
BCVA, ETDRS letters 55.84 4.15 85.87 0.29 <0.0001
Phenotype, Fishman classification 1.94 0.12 — —
Summary of demographic and clinical data from all Stargardt patients and healthy controls included in this study.
TABLE 2. Patient Characteristics
Patient Number Sex Age, y
Age of
Visual Acuity Phenotype Atrophy
Follow-UpOnset, y Right Left Right Left Right Left
S1 Female 42 35 82 80 2 2 — — FU
S2 Male 33 30 79 84 2 2 — — FU
S3 Male 53 40 41 36 2 2 — — FU
S4 Female 43 12 32 34 3 3 A A FU
S5 Female 33 28 75 28 1 1 — —
S6 Male 54 34 43 47 2 2 — —
S7 Male 45 18 21 21 3 3 A A FU
S8 Female 45 40 78 83 2 2 — — FU
S9 Female 43 37 73 60 2 2 — A FU
S10 Female 56 33 37 34 2 2 A A
S11 Female 47 42 85 85 1 1 — — FU
S12 Male 22 22 85 73 2 2 — —
S13 Female 30 24 57 75 1 1 — —
S14 Male 41 18 37 37 2 2 A A
S15 Male 31 28 70 53 3 3 — —
S16 Female 26 23 42 20 1 1 — —
Patient number, sex, age, age of onset, BCVA (ETDRS letters), fundus phenotype 1–3 according to Fishman classification, presence of areas with
geographic atrophy (A), 1-year follow-up (FU). Patients S4, S7, and S14 were siblings.
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used for maximal pupil dilation. Fluorescence lifetime images,
fundus color images (Zeiss FF 450plus; Zeiss, Oberkochen,
Germany), and OCT scans of the macula (Heidelberg Spectralis
HRAþOCT; Heidelberg Engineering, Heidelberg, Germany) of
both eyes were obtained.
This prospective study was conducted at the University
Hospital in Bern, Bern, Switzerland, with the approval of the
local ethics committee and in accordance with the Declaration
of Helsinki. Informed consent was obtained from all partici-
pants before study entry. This study is registered at Clinical-
Trials.gov as ‘‘Measurement of Retinal Auto Fluorescence with
a Fluorescence Lifetime Imaging Ophthalmoscope (FLIO
Group),’’ with the identifier number NCT01981148.
Fluorescence Lifetime Imaging Ophthalmoscope
A fluorescence lifetime imaging ophthalmoscope was used for
acquisition of retinal fluorescence lifetime data. It is based on a
HRA Spectralis system (Heidelberg Engineering). Basic principles
of the FLIO technique have been described in a previous study.26
Here, only a brief overview of the technique will be provided.
Retinal autofluorescence was excited using a 473-nm
pulsed laser and raster-scanning the central fundus with a
repetition rate of 80 MHz.
The laser safety calculations were provided by Heidelberg
Engineering and were done according to the International
Electrotechnical Commission (IEC) 60825-1:2007.29 This IEC
standard is a recognized consensus standard and equals to the
American National Standard for the Safe Use of Lasers (ANSI)
norm z136, which is only a national standard and not applicable
internationally.30 The following three different accessible emis-
sion limits (AELs) have been taken into account: (1) the exposure
from any single pulse within a pulse train shall not exceed the
AEL for a single pulse; (2) the average power for a pulse train of
emission duration T shall not exceed the power corresponding
to the AEL for a single pulse of duration T (with a thermal and a
photochemical limit); and (3) for constant pulse energy and
pulse duration, the energy per pulse shall not exceed the AEL for
a single pulse multiplied by the correction factor C5 (for detailed
calculations, see Supplementary Material S1). Thereby, in the
scanning beam within the FLIO system, the accessible emission
is below class I accessible emission limits.
The emitted fluorescence photons were detected by highly
sensitive hybrid photon-counting detectors (HPM-100-40;
Becker&Hickl, Berlin, Germany) in a short (498–560 nm;
SSC) and in a long (560–720 nm; LSC) spectral channel and
registered by time-correlated single-photon counting (TCSPC)
modules (SPC-150; Becker&Hickl). An infrared reflectance
image allows for tracking of eye movements and data
accumulation over the entire acquisition duration of approx-
imately 90 seconds. Becker&Hickl software (SPCImage 4.6)
was used for analysis of the recorded lifetime values. The
recorded single photons of the fluorescence decay were fitted
with a bi-exponential decay function and a binning factor of 1
for each pixel in both the SSC and LSC. The double-exponential
approximation of the fluorescence decay curve resulted in a
mean decay trace that is characterized by a short decay
component T1 with its relative amplitude (¼relative intensity)
a1 and a long decay component T2 with its relative amplitude
a2, whereby T1  T2 and a1  a2. The tau values T1 and T2
and the amplitudes a1 and a2 were then used for calculation of
the mean fluorescence lifetime Tm.
Tm ¼ a1*T1þ a2*T2
a1þ a2 ð1Þ
Tm represents the amplitude weighted mean fluorescence
decay time per pixel and wavelength channel.
Fluorescence Lifetime Data Analysis
The custom-made FLIO reader (ARTORG Center for Biomedical
Engineering Research, University of Bern, Bern, Switzerland)
was used for analysis of the mean retinal fluorescence lifetime
values within the areas of a standard ETDRS grid.26 The ETDRS
circle diameters were 1 mm for the central area, 3 mm for the
inner ring, and 6 mm for the outer ring. For detailed analysis of
specific retinal findings, mean fluorescence lifetime values
were averaged within an area with circle diameter of 0.16 mm.
This small circle was always placed within the area of the inner
ring of the standard ETDRS grid. For each single value, the
average of at least three independent measurements was taken.
In Vitro Measurements of Fluorescence Lifetimes
In vitro analysis of retinal and A2E were performed. All-trans
retinal (atRAL; Sigma-Aldrich, St. Louis, MO, USA) was dissolved
in ethanol (1 mg/mL). The sample was measured within a glass
test tube. The A2E was kindly provided by Janet R. Sparrow
(Department of Ophthalmology, Columbia University, New
York, NY, USA). A 200 lM solution was prepared using
methanol as dissolver. The A2E suspension was spread on a
glass chamber slide, and methanol was evaporated before
measurement. The samples were mounted on a porcelain plate
to avoid any background fluorescence, and FLIO measurement
was performed in a totally dark room. Data were analyzed in
both spectral channels using a binning factor of 5.
Statistical Analysis
Results are presented as mean 6 SEM. Mean values are
compared by Mann-Whitney test (two-tailed, confidence
interval 95%, significance level¼ 0.05). Statistical data analysis
was performed using Graph Pad Prism version 6 (GraphPad
Software, Inc., La Jolla, CA, USA). A stepwise forward
regression analysis was performed using SigmaPlot Version
12.3 (Systat Software, Inc., San Jose, CA, USA).
RESULTS
All 16 patients included in this study showed typical clinical
features of STGD, with well-defined hyperautofluorescent
flecks distributed around the macular center, spreading toward
the periphery. Twenty-eight percent of the eyes displayed
various degrees of areas with retinal atrophy, appearing black
in the autofluorescence measurement. Patient characteristics
are summarized in Tables 1 and 2.
Fundus Autofluorescence Lifetimes in Patients
With STGD
The fluorescence lifetimes of the fundus in patients with STGD
were in the range of age-matched healthy controls (SSC: 246 6 5
ps, range 219–312 ps, P¼ 0.38; LSC: 297 6 8 ps, range 226–401
ps, P ¼ 0.19). Hyperfluorescent flecks and atrophic areas were
clearly discernible in FLIO. Both areas were characterized by both
short and long autofluorescence lifetime values (Figs. 1, 2, 3A).
Autofluorescence Lifetimes Analysis in
Hyperfluorescent Flecks
Yellowish appearing flecks in the fundus examination corre-
sponded to hyperfluorescent areas in the fundus autofluores-
cence intensity images of both spectral channels (Fig. 1). In
lifetime measurements, flecks were clearly identifiable in both
channels as well. In the FLIO images, these areas were
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characterized by fluorescence lifetimes, which in the majority
(85% of the eyes) exhibited solely prolonged fluorescence
lifetimes (SSC: 441 6 10 ps; LSC: 446 6 8 ps). In 15% of the
eyes, additional flecks with shorter fluorescence lifetimes than
the surrounding tissue were identified (SSC: 262 6 14 ps; LSC:
242 6 4 ps). The discrimination between short and long
lifetime flecks was better in the LSC (Fig. 1). Flecks with short
lifetimes (red) seemed to be less hyperreflective in OCT than
those with long lifetimes (blue). Furthermore, red flecks were
predominantly seen in patients with just recent onset of visual
symptoms and an active disease progression with progressive
metamorphopsia and vision loss.
In the FLIO maps, additional areas with changes in
fluorescence lifetime values were clearly identifiable, which
were not detectable in autofluorescence intensity or color
fundus images (Figs. 1, 2, 4).
Autofluorescence Lifetimes Analysis in Atrophic
Areas
Atrophic areas, which are characterized by strongly decreased
fluorescence intensity, showed fluorescence lifetimes between
165 and 323 ps (256 6 15 ps) in the SSC and between 253 and
374 ps (323 6 15 ps) in the LSC (Fig. 2). There was no
morphologic correlation between areas with short and long
fluorescence lifetimes and corresponding areas in the OCT.
Autofluorescence Lifetimes Analysis in Different
Fishman Classification Groups
From the total of 32 eyes, 8 eyes (25%) were assigned to Fishman
I, 18 eyes (56%) to Fishman II, and 6 eyes (19%) to Fishman III. In
this study population, in eyes with Fishman I, no patient showed
atrophic areas, whereas in patients with Fishman III, no ‘‘normal
retina’’ could be analyzed. Short lifetime flecks were only seen in
patients with Fishman I.
Regression Analysis
Stepwise forward regression analysis was performed and
included the following factors: diagnosis of STGD, age, sex,
Fishman score, and the dependent variables mean fluores-
cence lifetime (Tm) in the SSC and the LSC. When analyzing
mean fluorescence lifetime values within the entire inner
ETDRS ring, the diagnosis of STGD (SSC: P < 0.001; LSC: P ¼
0.012) and age (SSC: P < 0.001; LSC: P ¼ 0.004) significantly
added to the ability of the equation to predict lifetimes in the
SSC or LSC. However, when analyzing contained areas of retina
FIGURE 1. Fundus autofluorescence lifetime map of the left eye of a patient with STGD (patient 11). Fundus AF and FLIOs in the short and long
spectral channel (SSC¼ 498–560 nm, LSC¼ 560–720 nm) with corresponding color fundus (CF), infrared (IR), and optical coherence tomography
(OCT 1–3) images. Corresponding locations in AF, FLIO, and OCT are marked with respective arrowheads.
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not affected by STGD-like changes, only age was identified as a
predictive factor within the SSC (P ¼ 0.002).
One-Year Follow-Up
In eight patients (50%), FLIO measurement was repeated after
a time interval of 12 months. After this time, BCVA did not
show significant deterioration compared with the baseline
measurement (P ¼ 0.86), although six of eight patients
reported mild decline of their vision. Color fundus images
and FAF images revealed different degrees of increase of
hyperfluorescent flecks and the area of atrophic lesions.
Individual flecks with short fluorescence lifetimes (red) were
observed to transform to long lifetimes (blue) (Fig. 4, red
arrow). During the study period, additional flecks with long
lifetime values appeared. Although mean fluorescence lifetime
values of the analyzed ETDRS areas featured slightly longer
lifetimes, the difference within 1 year was not statistically
significant (SSC: P ¼ 0.07; LSC: P ¼ 0.21).
Correlation of Fluorescence Lifetimes and Visual
Acuity
Assessed mean fluorescence lifetime values from the central
area of the ETDRS grid were correlated with BCVA (Fig. 3B).
Short fluorescence lifetimes were associated with a higher
ETDRS letter score than long fluorescence lifetimes in both
channels. Significant correlation was found between BCVA
(ETDRS letters) and fluorescence decay times in both spectral
channels (SSC: r2 ¼ 0.34, P ¼ 0.0005; LSC: r2 ¼ 0.29, P ¼
0.0014).
Analysis of Individual Fluorescence Lifetime
Components
The individual lifetimes T1 and T2 (short and long decay
components), which were used for calculation of the mean
fluorescence lifetime value Tm in the SSC and LSC (see
Equation 1), were further analyzed. Therefore, distribution
histograms T1 against T2 were depicted for each channel (Fig.
5).
In the healthy fundus, four lifetime clouds were clearly
identifiable (Fig. 5A): the principle lifetime cloud was built by
the neurosensory retina, whereas the central macula featured
shorter lifetime parameters, especially of T1 and the retinal
vessels, and the optic nerve head showed longer lifetime
components T2.
Hyperfluorescent flecks with long fluorescence lifetimes in
Stargardt patients were well discernible from other retinal
structures and featured longer lifetime components T1,
FIGURE 2. Stargardt disease (Fishman III) with central retinal atrophy and pigment accumulation (patient 4). Color fundus (CF), fundus AF, and FLIO
(short spectral channel) with indicated lines of the optical coherence tomography sections OCT 1–3. Corresponding locations in AF, FLIO, and OCT
are marked with respective arrowheads.
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whereas T2 remained largely unchanged (Fig. 5B). Patients
with additional short lifetime flecks (Fig. 5C) featured a
corresponding lifetime cloud that was characterized by shorter
T1 than the surrounding retina. Atrophic areas were charac-
terized by a shift of the parameter T2 to longer values (Fig. 5D).
FLIO Measurements In Vitro
atRAL and A2E, as a component of lipofuscin, exhibited strong
autofluorescence, especially in the LSC (560–720 nm). Mean
fluorescence lifetimes of A2E were between 350 and 450 ps in
the SSC and between 220 and 250 ps in the LSC. Fluorescence
decay time measurement of atRAL revealed extremely short
lifetimes Tm, T1, and T2 (LSC: Tm ¼ 38 ps). Fluorescence
lifetimes and distribution did not change by modifying the
concentration of the solution. Retinal, as a strong fluorophore,
dominated lifetime and distribution histograms in mixed
solutions, leading to a shift toward short lifetimes
(Supplementary Fig. S1).
FIGURE 3. (A) Quantitative analysis of retinal autofluorescence lifetimes in patients with STGD. Mean fluorescence lifetime values were evaluated
within the ETDRS grid shown (diameter central area c¼ 1 mm, inner ring IR¼ 3 mm, outer ring OR¼ 6 mm). The following areas within the inner
ETDRS ring were analyzed: hyperfluorescent spots () and atrophic areas (*) with short or long fluorescence lifetimes and surrounding retinal tissue
(&). Mean values from the short and the long spectral channel were compared with the healthy retina within the inner ETDRS ring in healthy control
eyes ( ) (n¼32 in the affected eyes and n¼15 in the control eyes; short spectral channel¼498–560 nm, long spectral channel¼560–720 nm; ns,
not significant). (B) Correlation of mean fluorescence lifetime with BCVA (ETDRS letters) for the short spectral channel (black circle, 498–560 nm;
r2 ¼ 0.34, P ¼ 0.0005) and the long spectral channel (gray square, 560–720 nm; r2 ¼ 0.29, P ¼ 0.0014).
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DISCUSSION
In the current study, we used a fluorescence lifetime imaging
ophthalmoscope for investigation of lifetime characteristics of
endogenous retinal fluorophores in patients with STGD.
Whereas areas without flecks and atrophy secondary to STGD
featured lifetime values comparable to age-matched healthy
controls, both hyperfluorescent flecks and hypofluorescent
atrophic lesions showed either shorter or longer lifetime
values.
There are various bis-retinoid pigments that can be
identified by mass spectroscopy and chromatography. All of
these components derive from atRAL that is released from
opsin after photoisomerization of ground state 11-cis-retinal
following capture of a photon of light (for a review see Ref.
31). It has been shown that atRAL accumulates in photore-
ceptor outer segments in patients with STGD.32 STGD is
caused by dysfunction of ABCR, which transports atRAL from
the inside to the outside of disc membranes. This leads to an
accumulation of atRAL condensation products and subse-
quently to degeneration of RPE and photoreceptors. Using
picosecond fluorometry, the lifetime (T1) of atRAL was
shown to be 31 ps.32 Our own measurements of pure retinal,
using an excitation wavelength of 473 nm, revealed mean
fluorescence decay times Tm of 38 ps in the emission channel
between 560 and 720 nm. However, retinal is only an
intermediate product and is rapidly reduced to atRAL by the
retinol dehydrogenase and further transformed to secondary
products such as A2E.33
In FLIO measurements of patients with STGD, we found a
vast range of fluorescence lifetimes within STGD lesions. Most
hyperfluorescent flecks, suggested to contain lipofuscin as a
major component, displayed longer lifetimes than the surround-
ing retina. The long fluorescence may also indicate a major
dysfunction of the underlying RPE due to accumulation of
lipofuscin and insufficient degradation. However, unexpectedly,
we found STGD lesions with the same appearance in the
autofluorescence intensity profile, displaying shorter lifetimes
than the surrounding retina. Our follow-up fluorescence lifetime
measurements suggest that the short lifetime lesions may turn
into lesions displaying the characteristic long lifetimes. It can
only be speculated at this point whether fluorophores from the
retinoid cycle within the early flecks cause these short lifetimes.
Further studies ex vivo and in suitable animal models, such as
the Abca4/ mouse, are needed to dissect the contributors of
retinal lifetimes and to evaluate whether the appearance of short
lifetime lesions serves as a marker for disease progression and
may be used to monitor therapeutic approaches. Another
powerful tool to study disease progression is the two-
dimensional (2D) plotting of the short and long lifetime
components (Fig. 5). Here, we show that specific retinal areas
like the macular center, the neuronal retina, the retinal vessels,
and the optic nerve head were clearly discernible within the 2D
plot in the healthy retina. This indicates that different
fluorophores with distinct decay characteristics, represented
by the short and the long decay components T1 and T2,
contribute to the mean fluorescence lifetime Tm. In STGD,
additional areas were identifiable, corresponding to hyper-
fluorescent areas with short or long fluorescence lifetimes and
to areas with geographic atrophy. FLIO potentially provides
additional information about the content and conformation of
endogenous fluorophores that could be used for monitoring of
retinal metabolic changes over the course of disease. By
analyzing lifetime data of in vitro measurements of atRAL and
A2E and comparing with in vivo FLIO data, one hypothesis
could be that retinal contributes to short fluorescence lifetimes
within hyperfluorescent lesions. Another possibility is that A2E,
which is a byproduct of the visual cycle and has short lifetimes
of approximately 250 ps, contributes to short lifetimes seen in
early flecks. On the other hand, high concentrations of other
lipofuscin components potentially originating from cell detritus
and stacked cells might lead to prolonged fluorescence decay
time in longer standing flecks. However, caution is needed
when extrapolating observations from ex vivo measurements
into in vivo conditions in the retina, as the fluorescence lifetime
signal in vivo derives from various endogenous fluorophores. A
recent study on near-infrared AF and short-wavelength (SW) AF
suggests that the RPE cell layer might already be altered or lost in
early stages of fleck formation. Thereby, the increased SW AF
signal within flecks might originate from augmented lipofuscin
formation within degenerating photoreceptor outer and inner
segments secondary to RPE atrophy.34
Interestingly, we did not find any differences in mean retinal
fluorescence lifetime values in areas of the fundus without
flecks of patients with STGD compared with age-matched
healthy controls, even though generally higher AF intensities
are expected in STGD.11 This supports the hypothesis that the
FIGURE 4. Disease progression within 1 year (patient 2). Color fundus
(CF), fundus AF, and FLIO (long spectral channel) with indicated lines
of the optical coherence tomography scan (OCT) (baseline, left). A 1-
year follow-up examination (right) shows clear disease progression
with accumulation of hyperfluorescent flecks. The red arrows mark
areas with short fluorescence lifetimes that converted to long lifetimes
within 1 year.
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FIGURE 5. Distribution of the short versus long fluorescence lifetime components T1 and T2. Distribution histograms with corresponding FLIO
(long spectral channel) are shown for a healthy 36-year-old subject (A), a Stargardt patient with long lifetime flecks (patient 3) (B), a Stargardt
patient with short and long lifetime flecks (patient 11) (C), and a Stargardt patient with central geographic atrophy (patient 10) (D). Specific areas
are highlighted according to the lifetime distribution clouds: normal retina (A1, B1, C1, D1), macular center (A2), retinal vessels (A3, B3, C3, D3),
optic nerve head (A4, B4, C4, D4), hyperfluorescent flecks (B2, C2, D2), and atrophic retinal area (D5).
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main fluorescence of the retina originates from components of
the visual cycle, mainly lipofuscin, within the RPE.10,14,20 As
fluorescence lifetimes are not dependent on the fluorophores
concentration, we did not expect any changes in fluorescence
lifetimes in cases with increased fluorescence intensity as seen
in STGD.25,35 Probably, retinal fluorescence indicates an
equilibrium of short and long decay components that is not
changed by equal increase of the components. On the other
hand, in areas with strongly increased autofluorescence
intensity, lifetimes can be shifted toward shorter or longer
lifetimes depending on the predominant fluorophore of the
lesions. This differentiation is an important finding, as it might
be used to assess disease activity and serve as control for future
therapies in the field of gene therapy and stem cell approaches.
Functionality of RPE cells might be quantified, and early
imbalance and dysfunction might be detected. However, there
is some controversy on lipofuscin toxicity. In particular, it is
unclear whether RPE degeneration is caused by excessive
lipofuscin accumulation or whether excessive lipofuscin
accumulation is caused by impaired autophagy and recycling
of retinoids by compromised RPE function.18
Atrophic lesions in STGD typically showed strongly
decreased autofluorescence intensity but were characterized
by both short and long fluorescence decay times. As the intact
retinal structure with preserved RPE contributes to short decay
times, the long lifetimes could be explained by the loss of the
retinal architecture and increased influence of underlying
structures such as the choroid. On the other hand, the short
lifetimes within atrophic areas were predominantly seen in the
central macular area, and given recent observations linking
macular pigment to short lifetimes, they are likely to originate
from macular pigment.36 However, the distribution of this
pigment seems to be strongly altered due to the underlying
disease and the destruction of the retinal layer architecture,
and therefore, this may be another marker for disease
progression.
This study has some limitations, which include the number
of patients measured and the naturally occurring heterogeneity
of the phenotypic appearance. Furthermore, a longer follow-
up time is necessary to confirm and refine FLIO markers for
disease progression of STGD. The diagnosis of STGD for this
study relies on the clinical assessment.
CONCLUSIONS
Analysis of retinal fluorescence lifetimes can be used to
characterize and differentiate hyperfluorescent lesions and
hypofluorescent atrophic areas in STGD. The change of
lifetimes over time may provide a useful tool to predict disease
progression and may be used to assess therapeutic effects in
upcoming clinical trials for STGD.
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